sodium iodide I 131, Iodotope, Sodium Iodide I 131 Therapeutic
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: sodium iodide I 131
BRAND NAME: Iodotope, Sodium Iodide I 131 Therapeutic
DRUG CLASS AND MECHANISM: Sodium iodide I 131 is an oral medication used to treat hyperthyroidism (overactive thyroid gland) and some cases of thyroid cancer. It falls under the category of an anti-thyroid drug but differs from the other anti-thyroid drugs, propylthiouracil (PTU) and methimazole (Tapazole), because it is radioactive. Sodium iodide I 131 is taken by mouth, readily absorbed into the body and is trapped within the thyroid gland. The trapped sodium iodide I 131 irradiates the thyroid gland thereby damaging it. As a result, the activity of the thyroid gland (that is, the production and release of thyroid hormone) is reduced. Excess sodium iodide I 131 is eliminated from the body in the urine by the kidneys. The sodium iodide retained in the body loses most of its radioactivity over several weeks. The half-life of the radioactivity is eight days. The FDA approved sodium iodide I 131 in August 1971.
GENERIC AVAILABLE: No
PREPARATIONS: Sodium iodide I 131also is available as a liquid in vials containing 5-150 mCi of radioactivity per capsule. (A millicurie is a unit for measuring radioactivity.)
STORAGE: Sodium iodide I 131 should be store at room temperature, 20-25 C (68-77 C). Sodium iodide I 131 is ordered for individual patients in a hospital setting. It arrives at room temperature in a lead container to minimize radiation exposure to hospital personnel. Special handling is required.
PRESCRIBED FOR: Sodium iodide I 131 is used to treat hyperthyroidism and some cases of thyroid cancer.
DOSING: The usual sodium iodide I 131 dose ranges from 4-10 mCi to treat hyperthyroidism. Doses to treat thyroid cancer are individualized and are usually 10-27 times greater than for hyperthyroidism.
DRUG INTERACTIONS: Non-radioactive iodine, thyroid hormone, propylthiouracil (PTU) or methimazole (Tapazole, Northyx) may all interfere with the trapping of sodium iodide I 131 by the thyroid gland. Thyroid hormone, drugs that contain iodine (for example, amiodarone [Coradone]), and iodine containing contrast agents all interfere with the action of sodium iodide I 131.
PREGNANCY: Sodium iodide I 131 has been shown to cause harm to a developing fetus. Use in pregnant women should be avoided.
NURSING MOTHERS: Iodine is excreted in breast milk. Therefore, formula feedings for infants are strongly recommended for nursing women requiring sodium iodide I 131 treatment.
SIDE EFFECTS: The side effects commonly seen with sodium iodide I 131 treatment are mild with the smaller doses given for hyperthyroidism but may be more severe with the larger doses given for thyroid cancer. Sodium iodide I 131 may cause suppression of the bone marrow, resulting in anemia, and reductions in white blood cells and platelets. It also may cause acute leukemia.
Thyroid crisis (due to the release of large amounts of thyroid hormone), severe inflammation of the salivary glands, and chromosomal abnormalities may occur. On day three after treatment, a constellation of signs and symptoms may occur including neck tenderness and swelling, pain with swallowing, sore throat, and cough. Finally, temporary hair thinning may occur two to three months after treatment.
Reference: FDA Prescribing Information
Last Editorial Review: 5/2/2012
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index